Catalyst
Slingshot members are tracking this event:
Cara Therapeutics (CARA) Expects Top-Line Data From Phase 2b Study of Oral CR845 in Chronic Pain Patients in First Half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CARA |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 29, 2017
Occurred Source:
http://ir.caratherapeutics.com/releasedetail.cfm?ReleaseID=1031842
Related Projects
- Another Opinion: A Discussion of Cara Therapeutics CR845 in development for acute and chronic pain and CKD associated pruritus in both an IV and oral version. CARA Executed On: May 08, 2017 at 10:00 AM EDT
- Discussion of Cara Therapeutics CR845 which is in development for acute and chronic pain and CKD associated pruritus in both an IV and oral version. CARA Executed On: Apr 11, 2017 at 02:30 PM EDT
Related Keywords
Top-line Data, Phase 2b Study, Oral Cr845, Chronic Pain Patients
